Last reviewed · How we verify
Cyclosporin
Cyclosporin is a Small molecule drug developed by Karolinska University Hospital. It is currently FDA-approved for Kawasaki's disease, Keratoconjunctivitis sicca, Prevention of Cardiac Transplant Rejection. Also known as: CsA (Cyclosporin), Restasis, Sandimmun, Neoral.
At a glance
| Generic name | Cyclosporin |
|---|---|
| Also known as | CsA (Cyclosporin), Restasis, Sandimmun, Neoral |
| Sponsor | Karolinska University Hospital |
| Target | Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Kawasaki's disease
- Keratoconjunctivitis sicca
- Prevention of Cardiac Transplant Rejection
- Prevention of Kidney Transplant Rejection
- Prevention of Liver Transplant Rejection
- Rheumatoid arthritis
- Severe Recalcitrant Psoriasis
- Tear film insufficiency
Common side effects
- Ocular burning
- Conjunctival hyperemia
- Discharge
- Epiphora
- Eye pain
- Foreign body sensation
- Pruritus
- Stinging
- Visual disturbance
Serious adverse events
- Severe angioedema
- Hypersensitivity
- Eye swelling
- Urticaria
- Face swelling
- Tongue swelling
- Pharyngeal edema
- Dyspnea
- Superficial injury of the eye
Key clinical trials
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
- Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy (PHASE2)
- Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis (NA)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclosporin CI brief — competitive landscape report
- Cyclosporin updates RSS · CI watch RSS
- Karolinska University Hospital portfolio CI
Frequently asked questions about Cyclosporin
What is Cyclosporin?
Cyclosporin is a Small molecule drug developed by Karolinska University Hospital, indicated for Kawasaki's disease, Keratoconjunctivitis sicca, Prevention of Cardiac Transplant Rejection.
What is Cyclosporin used for?
Cyclosporin is indicated for Kawasaki's disease, Keratoconjunctivitis sicca, Prevention of Cardiac Transplant Rejection, Prevention of Kidney Transplant Rejection, Prevention of Liver Transplant Rejection.
Who makes Cyclosporin?
Cyclosporin is developed and marketed by Karolinska University Hospital (see full Karolinska University Hospital pipeline at /company/karolinska-university-hospital).
Is Cyclosporin also known as anything else?
Cyclosporin is also known as CsA (Cyclosporin), Restasis, Sandimmun, Neoral.
What development phase is Cyclosporin in?
Cyclosporin is FDA-approved (marketed).
What are the side effects of Cyclosporin?
Common side effects of Cyclosporin include Ocular burning, Conjunctival hyperemia, Discharge, Epiphora, Eye pain, Foreign body sensation. Serious adverse events: Severe angioedema, Hypersensitivity, Eye swelling, Urticaria.
What does Cyclosporin target?
Cyclosporin targets Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2.
Related
- Target: All drugs targeting Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2
- Manufacturer: Karolinska University Hospital — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Kawasaki's disease
- Indication: Drugs for Keratoconjunctivitis sicca
- Indication: Drugs for Prevention of Cardiac Transplant Rejection
- Also known as: CsA (Cyclosporin), Restasis, Sandimmun, Neoral
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing